The pharmacokinetics of metronidazole, its biologically active alcohol metabolite, and its inactive acid metabolite were studied in five noninfected patients undergoing continuous ambulatory peritoneal dialysis and five patients undergoing hemodialysis. The latter were studied on off-dialysis days as a control group. Peritoneal dialysis caused insignificant changes in the apparent volume of distribution, elimination half-life, and total body clearance of metronidazole. Metronidazole (MT) is a nitroimidazole compound which has been widely used in the treatment of trichomoniasis, amebiasis, and giardiasis (7). Many studies have also documented the efficacy of MT in the treatment and prophylaxis of anaerobic infections (2). Twenty to thirty percent of an administered dose is excreted in the urine as the parent compound. The remainder is metabolized in the liver via conjugation and oxidation, with subsequent elimination of the metabolites in the urine and feces (13). The two major metabolites are the alcohol (MTOH) metabolite [1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole, which possesses 30% of the antimicrobial activity of MT] and the acid (MTAC) metabolite (2-methyl-5-nitro-1-imidazolyl acetic acid which is inactive) (2, 13). Hemodialysis (HD) removes significant amounts of MT and MTOH (4, 10, 12) . The effect of peritoneal dialysis (PD) on MT kinetics has been the subject of only one case report (9) . No dialysis pharmacokinetic data were presented, and serum-dialysate MT concentrations were measured by a nonspecific microbiological technique.
standard deviation]) accounted for only 8.9% of total body clearance (50.17 ± 18.64 ml/kg per h). Analysis of the 24-h area under the serum concentration versus time curves and peritoneal dialysis clearance data for the two metabolites suggested a similar insignificant effect of peritoneal dialysis on their elimination. Metronidazole dialysate concentrations in the first 6-h exchange ranged from 7.6 to 11.7 ,ug/ml. This would suggest that cumulative penetration of metronidazole from the systemic circulation into the peritoneal cavity with dosing every 8 h should lead to adequate concentrations for the treatment of anaerobic peritonitis. For the treatment of systemic anaerobic infections, it would appear at present that metronidazole dosage adjustments are not necessary in patients undergoing continuous ambulatory peritoneal dialysis. The potential for metabolite accumulation was noted in this study. If further studies confirm that excessive serum metabolite concentrations are toxic, dosage reduction in this group of patients may be warranted.
Metronidazole (MT) is a nitroimidazole compound which has been widely used in the treatment of trichomoniasis, amebiasis, and giardiasis (7) . Many studies have also documented the efficacy of MT in the treatment and prophylaxis of anaerobic infections (2) . Twenty to thirty percent of an administered dose is excreted in the urine as the parent compound. The remainder is metabolized in the liver via conjugation and oxidation, with subsequent elimination of the metabolites in the urine and feces (13) . The two major metabolites are the alcohol (MTOH) metabolite [1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole, which possesses 30% of the antimicrobial activity of MT] and the acid (MTAC) metabolite (2-methyl-5-nitro-1-imidazolyl acetic acid which is inactive) (2, 13) . Hemodialysis (HD) removes significant amounts of MT and MTOH (4, 10, 12) . The effect of peritoneal dialysis (PD) on MT kinetics has been the subject of only one case report (9) . No dialysis pharmacokinetic data were presented, and serum-dialysate MT concentrations were measured by a nonspecific microbiological technique.
This study was designed to rigorously examine the pharmacokinetics of MT, MTOH, and MTAC during continuous ambulatory peritoneal dialysis (CAPD), using data from HD patients on off-dialysis days as control data. The results of this study were then used to assess the need for dosage adjustment in patients undergoing CAPD.
MATERIALS AND METHODS
Patients. Five HD and five CAPD patients gave informed written consent to participate in this study. The 2, 3, 4, 6, 8, and 9 h after the end of the drug infusion. Blood samples were obtained by venipuncture from all patients at 24 h after the end of the drug infusion. In addition, blood samples were obtained by venipuncture at 48 h after the end of the drug infusion in the CAPD patients. Blood samples were allowed to clot and then centrifuged; the sera were saved for analysis.
Twenty-four hour (HD) and 24-and 48-h (CAPD) urine collections were also performed, and samples were saved after quantitation. Dialysate was collected every 6 h and quantitated, and samples were saved for analysis. Serum, urine, and dialysate samples were stored at -20°C until assayed.
Sample analysis. Biological samples were assayed for MT, MTOH, and MTAC content by a modification of the highpressure liquid chromatographic procedure of Kaye et al. (11) . MTOH, MTAC, and the internal standard [1-(2-hy- Figure 2 depicts the mean MTOH and MTAC serum concentrations versus time for the first 24 h after dosing for both groups (SD not illustrated for purposes of clarity). The serum MT concentration versus time curve was characterized by a curved a (distribution) phase and a linear 1 (elimination) phase in all but two subjects. These two subjects exhibited only a linear 1 phase. Table 2 shows the MT pharmacokinetic parameters in the two groups. Table 3 shows the metabolite pharmacokinetic parameters in the two groups. There were no significant differences between the groups in pharmacokinetic parameter comparisons.
In the CAPD group, MT PDC and RC constituted only 8.9 and 0.01% of TBC, respectively. This lack of significant effect of the peritoneal and renal routes on MT elimination in CAPD patients was reflected by the absence of a reduction in t1/2 or increase in TBC in the CAPD group compared to the HD group (Table 2 ). In addition, the presence of 2 liters of dialysate fluid in the peritoneal cavity for over 22 h/day exerted no significant effect on the Vd (Table 2 ). Table 4 shows the MT dialysate concentration data. MT dialysate concentrations ranged from 7.6 to 11.7 jig/ml in the first exchange down to 0.1 to 1.0 pug/ml in the eighth exchange. (Table 3) . Definitive conclusions regarding the peritoneal dialysability of these metabolites must await studies of systemic and PDC after intravenous administration of these compounds.
DISCUSSION
The purpose of this study was to assess the effect of CAPD on the pharmacokinetics of MT, MTOH, and MTAC and thus the need for changes in dosing recommendations. The mean elimination half-lives of 8.16 ± 1.59 and 10.93 ± 2.01 h in the HD and CAPD groups, respectively, are similar to those previously reported in patients without liver disease (6.2 to 10.0 h) (13) . The Vd and TBC data are also similar to those previously reported (13) .
Gabriel and co-workers studied the effect of an 8-h HD on the pharmacokinetics of MT, MTOH, and MTAC in 10 adult patients. Dialysance and amount removed during dialysis were not reported, but serum concentration data indicated a significant fall in MT concentration during the procedure (mean concentration predialysis, 5.46 ± 2.90 ,ug/ml; postdialysis, 0.41 ± 0.20 j,g/ml). MTOH was similarly removed (4). Ingham et al. described similar findings in a renal failure patient (10) .
More recently, Kreeft et al. examined the effect of a 6-h HD on the kinetics of MT, MTOH, and MTAC in five adult patients (12) . From data extrapolation, these authors suggested that up to 50% of the parent compound and metabolites after a single dose could be removed by an 8-h hemodialysis. Using weight-adjusted data from their study, mean calculated MT, MTOH, and MTAC HD clearances were 54.1, 59.6, and 107.5 ml/kg per h. This can be compared with the CAPD clearances noted in the present investigation (Tables 2 and 3 ). As MT PDC was only 8.9% of TBC, it would appear that supplemental doses, as recommended after HD, are not warranted. However, we as well as others (12) suggest that MT metabolites may accumulate in dialysis patients, especially those receiving CAPD, due to lower drug clearances. Several authors have suggested that accumulation of MT or its metabolites may predispose to neurotoxicity (1, 8, 14) . Should this possible link between excessive metabolite concentrations and toxicity be confirmed, dosage reduction may be necessary in this group of patients.
